Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Goserelin in Neoadjuvant TNBC
NCT03444025Phase 2Unknown
- Sponsor
- Kasr Al Ainy Hospital
- Start
- Mar 2018
- Primary completion
- Mar 2021
- Modality
- Peptides, Small Molecules
01
Overview
Phase 2, randomised trial of goserelin in triple-negative breast cancer (TNBC) (2 arms), sponsored by Kasr Al Ainy Hospital. Primary endpoint: Pathologic Complete Response Rate at 6 months. Status: unknown.
02
Drugs
goserelin
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03444025.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03444025.